Keywords: Vectura, VR315, Sandoz, Novartis, ALK Abello, allergy immunotherapy, Merck & Co

Vectura signs up Sandoz for asthma drug in RoW; good results for ALK Abello allergy immunotherapy

Article | 05 August 2011

Print This

There was another boost for UK inhalation product developer Vectura (LSE: VEC), which announced this morning that it has entered ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in